Dragonfly Receives Milestone Payment After First Patient Dosed in AbbVie's Phase 1 ABBV-303 Trial

On March 5, 2024, Dragonfly Therapeutics, a biotech firm specializing in innovative immunotherapies, announced the achievement of a significant financial milestone. This followed the administration of the first dose to a patient in a Phase 1 clinical study led by AbbVie, a renowned biopharmaceutical corporation listed on the New York Stock Exchange (NYSE: ABBV). The focus of the trial is ABBV-303, a promising therapeutic agent aimed at combating solid tumors, marking it as the sixth TriNKET® and the eighth overall drug candidate to leverage Dragonfly's proprietary platform technology in clinical trials.

The study, designated M24-122, is assessing the efficacy and safety of ABBV-303 both as a standalone treatment and in tandem with AbbVie's immunotherapy budigalimab (ABBV-181). Bill Haney, Dragonfly's CEO and co-founder, expressed enthusiasm about the collaboration with AbbVie, highlighting the latter's global prominence in developing innovative treatments for complex diseases and their role as an excellent partner in progressing new patient care options.

Interested parties can find more details on the M24-122 trial by visiting the ClinicalTrials.gov website, using the identifier NCT06158958.

Dragonfly Therapeutics is dedicated to the discovery, development, and commercialization of groundbreaking immunotherapies. The company boasts a robust pipeline of preclinical candidates, all identified through its proprietary platforms, and is actively advancing these towards clinical trials. Furthermore, Dragonfly maintains fruitful collaborations with industry leaders such as Merck, AbbVie, Gilead, and Bristol Myers Squibb, targeting a wide spectrum of diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!